SPOTLIGHT -
PARP inhibitors linked to increased risk of pneumonitis
PARP inhibitors are recent additions to the prostate cancer armamentarium and adverse event management is critical to their optimal integration into clinical practice.
AUA updates guideline on renal masses and localized renal cancer
The guideline was initially published in 2013 and was last amended in 2017.
ASCO 2021: Expert picks top GU cancer abstracts
Ahead of the 2021 ASCO Annual Meeting, Michael S. Cookson, MD, co-editor in chief of Urology Times, shared his thoughts on the most pivotal abstracts in genitourinary cancer.
FDA approves new subcutaneous formulation of leuprolide mesylate for prostate cancer
The new treatment is a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate.
FDA approves PSMA PET imaging agent 18F-DCFPyL for prostate cancer
The FDA has approved the PSMA PET imaging agent 18F-DCFPyL for use in prostate cancer.
Atezolizumab/cabozantinib combo continues to show promise in mCRPC
The updated data included 132 patients, all of whom had prior enzalutamide and/or abiraterone acetate.
FDA grants clearance to novel single-use cystoscope
The Uro-G single-use device arrives at a time when the FDA is actively investigating reports of infections associated with reusable cystoscopes.
Novel abiraterone formulation explored in phase 3 prostate cancer trial
The TAVT-45 formulation of abiraterone acetate consists of granules for oral suspension.
Study shows limitations of cystoscopy in detecting bladder cancer
Cystoscopy failed to detect residual muscle invasive bladder cancer in one-fourth of patients at the time of radical cystectomy.
Increased PSA screening linked to improved outcomes in younger African Americans
Higher screening frequency was associated with a lower risk of metastatic disease at diagnosis and a reduction in prostate cancer–specific mortality.
EU approves updated version of sacral neurostimulator for OAB
The device can now be marketed throughout the EU, as well as in Iceland, Liechtenstein, and Norway.
18F-fluciclovine PET/CT improves cancer control after prostatectomy
18F-fluciclovine-PET/CT imaging led to improved outcomes with postprostatectomy salvage radiotherapy versus conventional imaging.
Time to castration resistance impacts OS in mHSPC treated with combo regimens
In contrast, following development of metastatic castration-resistant prostate cancer, time to castration resistance did not influence overall survival.
No survival boost with add-on bevacizumab in frontline metastatic bladder cancer
Results of the phase 3 CALGB 90601 trial were published online in the Journal of Clinical Oncology.
Enfortumab vedotin nears bladder cancer approval in Japan
The antibody-drug conjugate received a priority review for patients with locally advanced or metastatic urothelial carcinoma with disease progression.
Enfortumab vedotin data published as FDA weighs expanded bladder cancer approval
The FDA is scheduled to make a decision on the expanded approval for the antibody-drug conjugate on or before August 17, 2021.
FDA accepts application for tadalafil/finasteride combo capsule for BPH
Tadfin is a once-daily capsule that combines 5 mg of tadalafil (Cialis) with 5 mg of finasteride (Proscar).
FDA grants breakthrough device designation to AI-based focal therapy system
The targeted focal laser ablation system is intended to be an office-based treatment for localized prostate cancer delivered under local anesthesia.
Study offers fresh insight into racial disparities in prostate cancer
Among the findings, the researchers identified a potential biomarker of ancestry-dependent treatment outcomes with hormone therapy.
Sexual function significantly improved after single incision sling for SUI
The study also showed that sexual function was comparable for women with SUI who received single incision sling versus those who underwent transobturator midurethral sling.
Pivotal data published for sacituzumab govitecan in bladder cancer
The data from the pivotal phase 2 TROPHY-U-01 trial supported the FDA approval of sacituzumab govitecan for the treatment of patients with urothelial carcinoma.
Pivotal long-term data published for apalutamide in mCSPC
The final results of the pivotal TITAN trial “support the early addition of apalutamide to ADT for optimal therapeutic outcomes in patients with metastatic castration-sensitive prostate cancer,” the authors wrote.
FDA authorizes trial of novel PSMA theranostics in mCRPC
The SECURE trial is exploring the PSMA PET imaging product 64Cu-SAR-bisPSMA and the PSMA targeted therapy 67Cu-SAR-bisPSMA.
Studies spotlight misinformation in YouTube bladder and prostate cancer videos
“Our findings highlight an urgent need for more accurate, patient-friendly social media content,” says Dr. Stacy Loeb.
FDA panel: atezolizumab, pembrolizumab should retain frontline bladder cancer approvals
Final FDA decision on approvals is still pending.
Initial 1-year data sustain lumasiran efficacy in PH1
Lumasiran is the first drug approved by the FDA for the treatment of patients with primary hyperoxaluria type 1.
Enzalutamide approved in EU for metastatic hormone-sensitive prostate cancer
The approval was based on data from the phase 3 ARCHES trial.
Combo of novel NTD inhibitor plus darolutamide explored in mCRPC
EPI-7386 previously received an FDA Fast Track Designation for patients with mCRPC resistant to standard-of-care treatments.
FDA grants targeted-release budesonide priority review for IgA nephropathy
The application for the targeted release formulation of budesonide is supported by data from the phase 3 NefIgArd trial and the phase 2 NEFIGAN trial.
SBRT safe in patients with prostate cancer and multiple metastases
Stereotactic body radiotherapy was not associated with any dose-limiting toxicities.